In the ann dated 20 Sept 2011 on ATL1102, ANP stated the comparison value of another Stem Cell Mobilisation therapy, Mobobil:
"One such complimentary therapy, Mozobil, has been approved for use in combination with the main agent G-CSF. First marketed in 2009, MozobilTM sales in 2010 were ~US$100Mill with peak sales potential estimated at US$350Mill per annum."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.786M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.9¢ | $1.1K | 126.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 6777725 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1490666 | 6 |
View Market Depth
| Last trade - 13.05pm 11/07/2025 (20 minute delay) ? |
| PER (ASX) Chart |